



Model-based optimal design of experiments with Pumas: `OptimalDesign.jl`

Jose Storopoli and Mohamed Tarek {jose.storopoli,mohamed}@pumas.ai
[PumasAI](#)

Outline

1. Motivation
2. Fisher Information Matrix – FIM
3. Optimal Design Objective
4. Optimal Design in Pumas
5. Selected Literature

Model-based

- M – parametric model.
- $\theta \in \Theta$ – model parameters.
- (M, Θ) – hypothesis.

Why Optimal Design?

- Which model M best describes the drug's effect?
- Which parameters θ are the best estimates?
- How to quantify the uncertainty in those θ ?

Which model M best describes the drug's effect?

Not committing to a particular model M_i and instead collecting data that would let us learn the parameter values of multiple models M_1, M_2, \dots, M_n simultaneously.

Which parameters θ are the best estimates?

Not committing to particular parameter values θ_i for each model M_i and instead using a set of values $\Theta_i : \theta_i \in \Theta_i$, e.g. a discrete set of specific parameter values or a continuous set.

How to quantify the uncertainty in those θ ?

Using the expected Fisher information matrix (FIM) instead of the observed one to estimate the expected standard errors at each parameter value $\theta_i \in \Theta_i$.

Fisher Information Matrix – FIM

- **Fisher information** is a way of measuring the amount of information that an observable random variable X carries about an unknown parameter θ upon which the probability of X depends.
- Formally, it is the expected value of the observed information, which in turn is the **negative of the second derivative of the loglikelihood**.
- if θ is *not* a scalar, then the information is expressed as a matrix, FIM, with the second derivative becoming the **Hessian matrix**:

$$- \mathbb{E}_{p(x|\theta)} [\mathbf{H}_{\log p(x|\theta)}]$$

Fisher Information Matrix Properties

- $N \times N$ positive semidefinite.
- symmetric, if second partial derivatives are all continuous.

Optimal Design Objective

There are a number of possible objectives that correspond to maximizing the information learned in the optimal experiment design:

- **A-optimality:**
 - **minimizing** the **trace** of the inverse of the expected FIM.
 - minimizing the sum of the expected standard errors.
- **D-optimality:**
 - **maximizing** the **determinant** of the expected FIM.
 - maximizing the product of the eigenvalues of the expected FIM.
 - which indirectly minimizes the expected standard errors.
- **T-optimality:**
 - **maximizing** the **trace** of the expected FIM.
 - maximizing the sum of the eigenvalues of the expected FIM.
 - which is also roughly correlated to minimizing the sum of the expected standard errors but giving more weight to the parameters with smaller standard errors.

Optimal Design in Pumas

- There are a number of degrees of freedom that an experiment designer can control when designing an experiment.
- This leads to different types of optimization problems, or so-called optimal design tasks.
- Currently¹, the main optimal design task supported in Pumas is the **sample time optimization**.

¹Pumas version 2.2

Sample Time Optimization

The following are assumed to be **fixed**:

- **model and parameter values**, e.g. from a similar study.
- **subjects' covariates**, a.k.a. subject templates, e.g. typical values in the target population.
- **number of replicas of each subject template**, using best practices in randomized sampling.
- **dosing regimen of each subject**, e.g. from initial simulations to avoid toxicity.
- **number of observations per subject template**.

The **only degree of freedom allowed to change is which times the observations are to be made for each subject template**.

Sample Time Optimization

The same optimal design task may be **repeated for different values of the other fixed degrees of freedom**, e.g. different dosing regimens or number of subjects/observations, to find a satisfactory design.

This parametric study is a form of naive **search-based, bi-level optimization**².

²Bilevel optimization is a special kind of optimization where one problem is embedded (nested) within another. The outer optimization task is commonly referred to as the upper-level optimization task, and the inner optimization task is commonly referred to as the lower-level optimization task.

Sample Time Optimization – Constraints

Some possible **constraints** to consider when doing sample time optimization are:

- **lower and upper bounds on the sample times**, e.g. the start and end date of the data collection part of the study.
- **minimum offset between any two consecutive observations.**
- **time window constraints**, e.g. the working hours of the clinical staff.
- **maximum and/or minimum number of measurements per time window.**

Selected Literature I

1. Aarons L and Ogungbenro K. Optimal Design of Pharmacokinetic Studies. en. Basic & Clinical Pharmacology & Toxicology 2010 Mar; 106:250–5. doi: 10.1111/j.1742-7843.2009.00533.x. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/j.1742-7843.2009.00533.x>
2. Atkinson AC. Commentary on 'Designs for dose-escalation trials with quantitative responses': COMMENTARY. en. Statistics in Medicine 2009 Dec; 28:3739–41. doi: 10.1002/sim.3736. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/sim.3736>
3. Bailey RA. Designs for dose-escalation trials with quantitative responses: DESIGNS FOR DOSE-ESCALATION TRIALS. en. Statistics in Medicine 2009 Dec; 28:3721–38. doi: 10.1002/sim.3646. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/sim.3646>
4. Bazzoli C, Retout S, and Mentré F. Fisher information matrix for nonlinear mixed effects multiple response models: Evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model. en. Statistics in Medicine 2009 Jun; 28:1940–56. doi: 10.1002/sim.3573. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/sim.3573>

Selected Literature II

5. Bretz F, Dette H, and Pinheiro JC. Practical considerations for optimal designs in clinical dose finding studies. en. *Statistics in Medicine* 2010 Mar; 29:731–42. doi: 10.1002/sim.3802. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/sim.3802>
6. Bretz F, Hsu J, Pinheiro J, and Liu Y. Dose Finding - A Challenge in Statistics. en. *Biometrical Journal* 2008 Aug; 50:480–504. doi: 10.1002/bimj.200810438. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/bimj.200810438>
7. Cella M, Gorter de Vries F, Burger D, Danhof M, and Della Pasqua O. A Model-Based Approach to Dose Selection in Early Pediatric Development. *Clinical Pharmacology & Therapeutics* 2010 Mar; 87:294–302. doi: 10.1038/clpt.2009.234. Available from: <http://doi.wiley.com/10.1038/clpt.2009.234>
8. Dette H, Bretz F, Pepelyshev A, and Pinheiro J. Optimal Designs for Dose-Finding Studies. en. *Journal of the American Statistical Association* 2008 Sep; 103:1225–37. doi: 10.1198/0162145080000000427. Available from: <https://www.tandfonline.com/doi/full/10.1198/0162145080000000427>

Selected Literature III

9. Dodds MG, Hooker AC, and Vicini P. Robust Population Pharmacokinetic Experiment Design. en. Journal of Pharmacokinetics and Pharmacodynamics 2005 Feb; 32:33–64. doi: 10.1007/s10928-005-2102-z. Available from: <http://link.springer.com/10.1007/s10928-005-2102-z>
10. Dragalin V and Fedorov V. Adaptive designs for dose-finding based on efficacy–toxicity response. en. Journal of Statistical Planning and Inference 2006 Jun; 136:1800–23. doi: 10.1016/j.jspi.2005.08.005. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0378375805001862>
11. Duffull SB, Retout S, and Mentré F. The use of simulated annealing for finding optimal population designs. en. Computer Methods and Programs in Biomedicine 2002 Jul; 69:25–35. doi: 10.1016/S0169-2607(01)00178-X. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S016926070100178X>
12. Hooker A and Vicini P. Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments. en. The AAPS Journal 2005 Dec; 7:E759–E785. doi: 10.1208/aapsj070476. Available from: <http://link.springer.com/10.1208/aapsj070476>

Selected Literature IV

13. Hooker AC, Foracchia M, Dodds MG, and Vicini P. An Evaluation of Population D-Optimal Designs Via Pharmacokinetic Simulations. en. Annals of Biomedical Engineering 2003 Jan; 31:98–111. doi: 10.1114/1.1533074. Available from: <http://link.springer.com/10.1114/1.1533074>
14. Lledó-García R, Hennig S, Nyberg J, Hooker AC, and Karlsson MO. Ethically Attractive Dose-Finding Designs for Drugs With a Narrow Therapeutic Index. en. The Journal of Clinical Pharmacology 2012 Jan; 52:29–38. doi: 10.1177/0091270010390041. Available from: <http://doi.wiley.com/10.1177/0091270010390041>
15. Maloney A, Karlsson MO, and Simonsson USH. Optimal Adaptive Design in Clinical Drug Development: A Simulation Example. en. The Journal of Clinical Pharmacology 2007 Oct; 47:1231–43. doi: 10.1177/0091270007308033. Available from: <http://doi.wiley.com/10.1177/0091270007308033>
16. Mentre F. Optimal design in random-effects regression models. en. Biometrika 1997 Jun; 84:429–42. doi: 10.1093/biomet/84.2.429. Available from: <https://academic.oup.com/biomet/article-lookup/doi/10.1093/biomet/84.2.429>

Selected Literature V

17. Nyberg J, Karlsson MO, and Hooker AC. Simultaneous optimal experimental design on dose and sample times. en. *Journal of Pharmacokinetics and Pharmacodynamics* 2009 Apr; 36:125–45. doi: 10.1007/s10928-009-9114-z. Available from: <http://link.springer.com/10.1007/s10928-009-9114-z>
18. Retout S, Comets E, Samson A, and Mentré F. Design in nonlinear mixed effects models: Optimization using the Fedorov–Wynn algorithm and power of the Wald test for binary covariates. en. *Statistics in Medicine* 2007 Dec; 26:5162–79. doi: 10.1002/sim.2910. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/sim.2910>
19. Retout S, Duffull S, and Mentré F. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. en. *Computer Methods and Programs in Biomedicine* 2001 May; 65:141–51. doi: 10.1016/S0169-2607(00)00117-6. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0169260700001176>
20. Tod M, Mentré F, Merlé Y, and Mallet A. Robust Optimal Design for the Estimation of Hyperparameters in Population Pharmacokinetics. en. *Journal of Pharmacokinetics and Biopharmaceutics* 1998 Dec; 26:689–716. doi: 10.1023/A:1020703007613. Available from: <https://doi.org/10.1023/A:1020703007613>

Selected Literature VI

21. Strouwen A. Optimal Design of Dynamic Experiments in Bioscience Engineering. 2021